BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 36119068)

  • 21. Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma.
    Liu J; Shen H; Gu W; Zheng H; Wang Y; Ma G; Du J
    Front Immunol; 2022; 13():960738. PubMed ID: 36032135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mast cell-based molecular subtypes and signature associated with clinical outcome in early-stage lung adenocarcinoma.
    Bao X; Shi R; Zhao T; Wang Y
    Mol Oncol; 2020 May; 14(5):917-932. PubMed ID: 32175651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma.
    Li X; Dai Z; Wu X; Zhang N; Zhang H; Wang Z; Zhang X; Liang X; Luo P; Zhang J; Liu Z; Zhou Y; Cheng Q; Chang R
    Front Immunol; 2022; 13():749241. PubMed ID: 35529878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validating a Macrophage Marker Gene Signature (MMGS) in Lung Adenocarcinoma Prognosis and Response to Immunotherapy.
    Song P; Wusiman D; Li W; Guo L; Ying J; Gao S; He J
    J Immunother; 2023 Jul-Aug 01; 46(6):205-215. PubMed ID: 37220007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction and analysis of a novel ferroptosis-related gene signature predicting prognosis in lung adenocarcinoma.
    Zhou J; Wang X; Li Z; Jiang R
    FEBS Open Bio; 2021 Nov; 11(11):3005-3018. PubMed ID: 34499810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
    Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
    BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Novel Nucleic Acid Sensing-related Genes Signature for Predicting Immunotherapy Efficacy and Prognosis of Lung Adenocarcinoma.
    Peng X; Wu H; Zhang B; Xu C; Lang J
    Curr Cancer Drug Targets; 2024; 24(4):425-444. PubMed ID: 37592781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma.
    Jiang H; Xu S; Chen C
    BMC Cancer; 2020 Aug; 20(1):782. PubMed ID: 32819300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a TGF-β signaling-related gene signature for prediction of immunotherapy and targeted therapy for lung adenocarcinoma.
    Yu Q; Zhao L; Yan XX; Li Y; Chen XY; Hu XH; Bu Q; Lv XP
    World J Surg Oncol; 2022 Jun; 20(1):183. PubMed ID: 35668494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
    Zou X; Hu Z; Huang C; Chang J
    Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma.
    Song Q; Shang J; Yang Z; Zhang L; Zhang C; Chen J; Wu X
    J Transl Med; 2019 Mar; 17(1):70. PubMed ID: 30832680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune- and Stemness-Related Genes Revealed by Comprehensive Analysis and Validation for Cancer Immunity and Prognosis and Its Nomogram in Lung Adenocarcinoma.
    Chen M; Wang X; Wang W; Gui X; Li Z
    Front Immunol; 2022; 13():829057. PubMed ID: 35833114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An
    Han Y; Wong FC; Wang D; Kahlert C
    Cancer Inform; 2022; 21():11769351221100727. PubMed ID: 35645555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and Validation of a Seven-Gene Signature for Predicting the Prognosis of Lung Adenocarcinoma.
    Zhang Y; Zhang X; Lv X; Zhang M; Gao X; Liu J; Xu Y; Fang Z; Chen W
    Biomed Res Int; 2020; 2020():1836542. PubMed ID: 33195688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and validation of a nomogram with an epigenetic signature for predicting survival in patients with lung adenocarcinoma.
    Wang J; He L; Tang Y; Li D; Yang Y; Zeng Z
    Aging (Albany NY); 2020 Nov; 12(22):23200-23216. PubMed ID: 33221751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic signature of lung adenocarcinoma based on stem cell-related genes.
    Huang Z; Shi M; Zhou H; Wang J; Zhang HJ; Shi J-
    Sci Rep; 2021 Jan; 11(1):1687. PubMed ID: 33462260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification and Validation of a Three Pyroptosis-Related lncRNA Signature for Prognosis Prediction in Lung Adenocarcinoma.
    Liu J; Liu Q; Shen H; Liu Y; Wang Y; Wang G; Du J
    Front Genet; 2022; 13():838624. PubMed ID: 35928454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
    Front Immunol; 2021; 12():723172. PubMed ID: 34539658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma.
    Han T; Liu Y; Wu J; Bai Y; Zhou J; Hu C; Zhang W; Guo J; Wang Q; Hu D
    Sci Rep; 2023 Mar; 13(1):5153. PubMed ID: 36991102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.